For example, trials targeting the PD-L1/PD1 checkpoint in NSCLC and head and neck cancer have evaluated the predictive power of PDL1 expression on CTCs, however the results have been inconsistent [20,38]. This evidence concerns the gene RPL17 and non-small cell lung carcinoma.